Skip to main navigation Skip to search Skip to main content

B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates

  • Chengyang Liu
  • , Hooman Noorchashm
  • , Jennifer A. Sutter
  • , Mina Naji
  • , Eline Luning Prak
  • , Jean Boyer
  • , Taryn Green
  • , Michael R. Rickels
  • , John E. Tomaszewski
  • , Brigitte Koeberlein
  • , Zhonglin Wang
  • , Michelle E. Paessler
  • , Ergun Velidedeoglu
  • , Susan Y. Rostami
  • , Ming Yu
  • , Clyde F. Barker
  • , Ali Naji
  • University of Pennsylvania
  • Children's Hospital of Philadelphia

Research output: Contribution to journalArticlepeer-review

136 Scopus citations

Abstract

We found that an induction immunotherapy regimen consisting of rabbit anti-thymocyte globulin (Thymoglobulin) and the monoclonal antibody to CD20 rituximab (Rituxan) promoted long-term islet allograft survival in cynomolgus macaques maintained on rapamycin monotherapy. B lymphocyte reconstitution after rituximab-mediated depletion was characterized by a preponderance of immature and transitional cells, whose persistence was associated with long-term islet allograft survival. Development of donor-specific alloantibodies was abrogated only in the setting of continued rapamycin monotherapy.

Original languageEnglish
Pages (from-to)1295-1298
Number of pages4
JournalNature Medicine
Volume13
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Dive into the research topics of 'B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates'. Together they form a unique fingerprint.

Cite this